Plain-English translation of NCT06767306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining stereotactic body radiotherapy (a precise, focused form of radiation) with standard immune checkpoint inhibitor medications works better than immune therapy alone for people with advanced melanoma. Radiation can help 'wake up' the immune system to fight cancer more effectively. Researchers believe this combination may help more patients respond to treatment and survive longer.
Early research suggests that radiation and immune therapy work together synergistically—meaning they enhance each other's cancer-fighting power. While immune therapy alone helps some patients with advanced melanoma, this trial aims to see whether adding radiation can improve survival rates and response rates without causing more side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group receives the focused radiation therapy combined with immune checkpoint inhibitor medication over several months, while the other group receives the immune medication alone. If you receive radiation, it will be delivered to all your tumor sites between the first and third cycles of your immune therapy. Throughout the trial, you'll have regular doctor visits, imaging scans, and blood tests to monitor how you're responding and track any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Australia
Canada